Continuing Education

CME Credits for Physicians

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Jefferson Medical College (JMC) and the Alzheimer’s Association. Jefferson Medical College is accredited by the ACCME to provide continuing medical education for physicians.

Jefferson Medical College designates this educational activity for a maximum of 13.75 AMA PRA Category 1 Credits™. Each physician should claim only those credits that he/she actually spent in the activity.

Jefferson Medical College designates the Imaging pre-conference course for up to 7.5 AMA PRA Category 1 Credits™ and the Basic Science pre-conference course for up to 6.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CE for Psychologists

The Alzheimer’s Association is approved by the American Psychological Association to sponsor continuing education for psychologists. The Alzheimer’s Association maintains responsibility for this program and its content. There are up to 21.25 continuing education credit hours available for psychologists for these educational activities. Psychologists should only claim credit commensurate with the extent of their participation in the activity.

Obtaining CE/CME

Participants who qualify for CE or CME credits must pay a $50 registration fee for each professional certificate, attend sessions claimed for credit in their entirety, complete an attendance form, and complete the appropriate online evaluation forms to receive continuing education credits. You will receive a continuing education packet that contains the attendance form and a Continuing Education Fact Sheet with instructions at the Continuing Education counter. The Fact Sheet is also in your conference bag.

Statement of Need, Purpose and Objective

The International Conference on Prevention of Dementia is organized to foster interdisciplinary interactions among health care, research, clinical and administrative professionals concerned with aging and Alzheimer’s disease. In addition to the core plenary and symposia sessions, oral and poster sessions will be presented to encourage and stimulate diverse viewpoints in research, treatment and care. Two full-day programs will also be offered on the Imaging of Alzheimer’s Disease and Targeting Multiple Neurodegenerative Pathways for Alzheimer Drug Discovery.

The 2007 Conference will focus on:

• Advancing research on prevention and early detection of dementia
• Stimulating new explorations while identifying barriers to progress
• Sharing scientific information in clear, non-specialist language
• Transferring technology and knowledge across disciplines
• Fostering cooperative, international investigations

Target Audience

This conference is targeted to:

• Biochemists
• Geriatric psychiatrists
• Geriatric specialists
• National policy advocates
• Policy makers
• Primary care physicians
• Neurologists
• Neuroscientists
• Pharmacologists
• Psychiatrists
• Psychologists
• Radiologists

Learning Objectives

At the conclusion of this conference, participants should be able to:

• Identify emerging strategies in imaging, biomarkers, genetics, and proteomics that may enable earlier diagnosis of dementia, identify individuals at risk, and improve tracking of disease progression
• Explain the epidemiological and biological evidence linking various lifestyle factors to improved likelihood of maintaining cognitive health or increased risk for decline
• Discuss potentially disease-modifying emerging compounds, including homocysteine, R-flurbiprofen, xaliprodem, rosiglitazone, and immunotherapy
• Contrast neurological and cognitive changes associated with normal aging with decline involved in neurodegenerative processes
• Summarize key issues in primary prevention of dementia, including challenges in prevention trial design, case identification, epidemiological considerations and monitoring cognitive change over time
• Describe the public health impact and policy implications of cognitive decline
• Explain the role of cardiovascular risk factors in cognitive decline and dementia.